Source-grounded facts extracted from IRONWOOD PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IRONWOOD PHARMACEUTICALS INC shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for 2026 at the 2026-06-16 meeting.
“4. The stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for 2026, based on the following votes: For Against Abstain Broker Non-Votes 121,957,895 2,783,154 343,639 -”
IRONWOOD PHARMACEUTICALS INC shareholders approved Approval of Plan Amendment to increase authorized shares under the Amended and Restated 2019 Equity Incentive Plan at the 2026-06-16 meeting.
“3. The stockholders approved the Plan Amendment, based on the following votes: For Against Abstain Broker Non-Votes 104,066,785 5,404,112 166,807 15,446,984”
IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-16 meeting.
“2. The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement for the Annual Meeting, based on the following votes: For Against Abstain Broker Non-Votes 104,461,936 4,958,394 217,374 15,446,984”
IRONWOOD PHARMACEUTICALS INC shareholders approved Election of eight director nominees to serve on the board of directors for a one-year term at the 2026-06-16 meeting.
“1. The stockholders elected eight director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes: Director Nominee For Withheld Broker Non-Votes Mark Currie, Ph.D. 107,222,711 2,414,993 15,446,984 Alexander Denner, Ph.D. 104,323,731 5,313,973 15,446,984 Jon Duane 105,956,515 3,681,189 15,446,984 Marla Kessler 107,142,336 2,495,368 15,446,984 Thomas McCourt 107,152,086 2,485,618 15,446,984 Julie McHugh 104,403,033 5,234,671 15,446,984 Catherine Moukheibir 106,410,985 3,226,719 15,446,984 Jay Shepard 107,209,046 2,428,658 15,446,984”
Ronald Silver was appointed as interim chief financial officer at IRONWOOD PHARMACEUTICALS INC.
“On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250”
Ronald Silver was appointed as interim chief financial officer and principal financial officer at IRONWOOD PHARMACEUTICALS INC.
“Effective May 15, 2026, Ronald Silver, age 44, the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer, will also serve as the Company’s interim chief financial officer and principal financial officer.”
Gregory Martini departed as Senior Vice President, Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.
“On May 8, 2026, Gregory Martini notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026.”
IRONWOOD PHARMACEUTICALS INC reported first quarter 2026 results: revenue $ 106,506, net income 40,773, EPS 0.25. Guidance reaffirmed.
“First Quarter 2026 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2026 Q1 2025 Total revenue $ 106,506 $ 41,143 Total costs and expenses 33,933 70,251 GAAP net income (loss) 40,773 (37,386 ) GAAP net income (loss) – per share basic 0.25 (0.23 ) GAAP net income (loss) – per share diluted 0.24 (0.23 ) Adjusted EBITDA 2 76,671 (4,742 ) Non-GAAP net income (loss) 40,945 (23,228 ) Non-GAAP net income (loss) per share – basic 0.25 (0.14 ) Non-GAAP net income (loss) per share – diluted 0.24 (0.14 )”
IRONWOOD PHARMACEUTICALS INC amended Third Amendment to Amended and Restated Exclusive License Agreement with Ferring International Center S.A. valued at $12.5 million aggregate payment to Ferring, including an initial payment of $7.5 million and a secon (effective 2025-12-18).
“On December 18, 2025, Ironwood Pharmaceuticals, Inc. (the "Company"), solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company ("VectivBio"), and Ferring International Center S.A. ("Ferring"), entered into that certain third amendment (the "Amendment") to the amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and between GlyPharma Therapeutic Inc. (as predecessor to VectivBio) and Ferring (the "Ferring License Agreement").”
IRONWOOD PHARMACEUTICALS INC engaged KPMG LLP as its auditor.
“On July 3, 2025, the Audit Committee approved the appointment of KPMG to serve as the Company’s new independent registered public accounting firm, effective immediately, for the fiscal year ending December 31, 2025.”
IRONWOOD PHARMACEUTICALS INC dismissed Ernst & Young LLP as its auditor.
“On July 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.”
IRONWOOD PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“the last 30 consecutive business days, the bid price for the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The deficiency letter has no immediate effect on the listing of the Company’s securities on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided a period of 180 calendar days, or u”
IRONWOOD PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“daq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC. The Notice states that the Company has 60 calendar days from the date of the Notice, or until May 20, 2025, to submit a plan to regain compliance with the Rule. If Nas”
IRONWOOD PHARMACEUTICALS INC announced a restructuring with charges of approximately $20.0 million to approximately $25.0 million (approximately 50%).
“to have approximately 120 full-time employees. The Company estimates that, in connection with this reduction in its workforce, it will incur aggregate charges of approximately $20.0 million to approximately $25.0 million, primarily comprised of one-time employee severance and benefit costs. The charges related to the reduction in workforce are expected to be”
Thomas McCourt changed role as principal executive officer at IRONWOOD PHARMACEUTICALS INC.
“Mr. Martini will assume the responsibilities of the Company’s principal financial officer from Thomas McCourt, who will remain the Company’s principal executive officer.”
Gregory Martini was appointed as Senior Vice President, Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.
“the Company announced the promotion of Gregory Martini, 36, to Senior Vice President, Chief Financial Officer.”
Andrew Davis departed as Senior Vice President, Chief Business Officer at IRONWOOD PHARMACEUTICALS INC.
“Andrew Davis notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Business Officer, effective November 22, 2024.”
Sravan K. Emany was appointed as Senior Vice President, Chief Operating Officer and Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.
“On June 18, 2024, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, age 46, the Company’s Senior Vice President, Chief Financial Officer, to the position of Senior Vice President, Chief Operating Officer and Chief Financial Officer, effective immediately.”
IRONWOOD PHARMACEUTICALS INC reported first quarter 2024 results: revenue $74,877, net income $(4,162), EPS $(0.03).
“growth, and delivering sustained profits and cash flow.” First Quarter 2024 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2024 Q1 2023 Total revenue 2 $ 74,877 $ 104,061 Total operating expenses 63,857 43,964 GAAP net income (loss) 2 (4,162 ) 45,714 GAAP net income (loss) – per share basic 2 (0.03 ) 0.30 GAAP net income (loss) – per”
IRONWOOD PHARMACEUTICALS INC reported the year ended December 31, 2023 results: revenue $ 442,735, net income (1,002,239), EPS (6.45).
“Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96”
IRONWOOD PHARMACEUTICALS INC reported the quarter ended December 31, 2023 results: revenue $ 117,553, net income (1,087), EPS (0.01).
“Fourth Quarter and Full Year 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q4 2023 Q4 2022 FY 2023 FY 2022 Total revenues $ 117,553 $ 107,199 $ 442,735 $ 410,596 Total operating expenses 2 79,964 38,836 1,388,165 160,259 GAAP net income (loss) 2 (1,745 ) 48,867 (1,031,559 ) 175,065 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2 (1,087 ) - (1,002,239 ) - GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – basic (0.01 ) 0.32 (6.45 ) 1.13 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. per share – diluted (0.01 ) 0.27 (6.45 ) 0.96”
IRONWOOD PHARMACEUTICALS INC reported full year 2024 results: revenue $435 - $455 million. Guidance initiated.
“- 8% Low-single digits % High-single digit prescription demand growth offset by mid to high-single digit price erosion primarily due to Medicaid AMP cap removal Total revenue $435 - $450 million $435 - $455 million Adjusted EBITDA 1 ~($900) million Reflects ~$1.1 billion one-time charge from acquisition of VectivBio >$150 million Excludes potential”
IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue Total revenues $ 113,739 $ 108,637, net income GAAP net income 13,950 50,317, EPS GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28. Guidance reaffirmed.
“the year and meaningful pipeline catalysts ahead in 2024.” Third Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q3 2023 Q3 2022 Total revenues $ 113,739 $ 108,637 Total operating expenses 73,716 40,164 GAAP net income 13,950 50,317 GAAP net income attributable to Ironwood Pharmaceuticals, Inc. 15,321 50,317 GAAP net income”
IRONWOOD PHARMACEUTICALS INC reported second quarter 2023 results: revenue $107,382, net income $(1,089,478), EPS $(6.84) per share – basic. Guidance raised.
“position, and grow Ironwood’s leadership within GI.” Second Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 2Q 2023 2Q 2022 Total revenues $ 107,382 $ 97,231 Total operating expenses 2 1,190,521 41,576 GAAP net income (loss) 2 (1,089,478 ) 37,080 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2”
IRONWOOD PHARMACEUTICALS INC incurred revolving credit of $400,000,000 with Wells Fargo Bank, N.A..
“On June 29, 2023, Ironwood borrowed $400,000,000 under the Revolving Credit Agreement to fund a portion of the consideration paid to purchase the Shares in connection with the Offer.”
IRONWOOD PHARMACEUTICALS INC shareholders approved Ratification of Ernst & Young LLP as independent auditor for 2023 at the 2023-06-20 meeting.
“The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023, based on the following votes:”
IRONWOOD PHARMACEUTICALS INC shareholders approved Approval of Amended and Restated 2019 Equity Incentive Plan at the 2023-06-20 meeting.
“The stockholders approved the Company’s Plan, based on the following votes:”
IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote on frequency of future say-on-pay votes (every year) at the 2023-06-20 meeting.
“The stockholders recommended, on a non-binding advisory basis, that future non-binding advisory votes to approve the compensation of the Company’s named executive officers, be held once every year, based on the following votes:”
IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote to approve named executive officer compensation at the 2023-06-20 meeting.
“The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting, based on the following votes:”
IRONWOOD PHARMACEUTICALS INC shareholders approved Election of nine directors at the 2023-06-20 meeting.
“The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes:”
IRONWOOD PHARMACEUTICALS INC incurred revolving credit.
“The information included under Item 1.01 above under the heading "Revolving Credit Agreement" is incorporated herein by reference.”
IRONWOOD PHARMACEUTICALS INC entered into Transaction Agreement with VectivBio Holding AG (effective 2023-05-21).
“On May 21, 2023, Ironwood Pharmaceuticals, Inc., a Delaware corporation (“Ironwood”), entered into a Transaction Agreement (the “Transaction Agreement”) with VectivBio Holding AG”
IRONWOOD PHARMACEUTICALS INC reported first quarter 2023 results: revenue $ 104,061, net income 45,714, EPS 0.30. Guidance reaffirmed.
“supporting the next growth horizon for the company.” First Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 1Q 2023 1Q 2022 Total revenues $ 104,061 $ 97,529 Total operating expenses 43,964 39,683 GAAP net income 45,714 38,801 GAAP net income per share – basic 0.30 0.25 GAAP net income per share –diluted 0.25 0.21 Adjusted”
Jason Rickard departed as Senior Vice President, Chief Operating Officer at IRONWOOD PHARMACEUTICALS INC.
“Accordingly, Jason Rickard’s last day as Senior Vice President, Chief Operating Officer, and as an employee of the Company, will be May 12, 2023.”
IRONWOOD PHARMACEUTICALS INC reported financial results for quarter and year ended December 31, 2022.
“On February 16, 2023, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter and year ended December 31, 2022.”
IRONWOOD PHARMACEUTICALS INC reported full year 2022 results: revenue ~$411 million. Guidance reaffirmed.
“expects: Previous 2022 Guidance (November 2022) Updated 2022 Guidance 1 LINZESS U.S. net sales growth 2 Low single digits % ~0% Total revenue $420 - $430 million ~$411 million Adjusted EBITDA 3 >$250 million ~$250 million Full Year 2023 Financial Guidance The table below summarizes Ironwood’s full year 2023 guidance. Ironwood expects: 2023 Guidance”
IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2022 results: revenue $108,637, net income $50,317, EPS $0.33. Guidance reaffirmed.
“allocation continue to position our company for growth.” Third Quarter 2022 Financial Highlights 1 (in thousands, except for per share amounts) 3Q 2022 3Q 2021 Total revenues $ 108,637 $ 103,747 Total operating expenses 40,164 38,576 GAAP net income 50,317 55,845 GAAP net income per share – basic 0.33 0.34 GAAP net income per share – diluted 0.28 0.34 Adjusted”
Sravan K. Emany was appointed as Senior Vice President, Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.
“On November 29, 2021, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, 44, as the Company’s Senior Vice President, Chief Financial Officer, effective December 6, 2021 (the “Effective Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.